Project Grant HT94252311032
Award Date 9/30/23
Completion Date 9/29/27
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $749,996 to the Institute of Cancer Research: Royal Cancer Hospital (The) on August 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) for the project "BAK-LOSS Lethal Prostate Cancer: Uncovering Therapeutic Vulnerabilities to Deliver New Treatments and Improve Clinical Outcomes." The four-year award, extending through July 31, 2029, supports research conducted in Great...
- The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
- The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...
- The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
- The University of Cambridge received a $1,996,828.00 four-year Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research to develop predictive models for treatment response, early relapse, and survival in breast cancer across molecular subtypes. The University will leverage multi-modal data integration techniques to explore early signals of later metastatic recurrence. This research aims to...
- This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
- The Department of the Army Medical Command awarded a $699,534 project grant to the Institute of Cancer Research: Royal Cancer Hospital under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will support research on B7-H3 (CD276) as a therapeutic target in lethal prostate cancers. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...
- This Defense Health Agency (DHA) Project Grant award for $4,509,475.00, granted on Sep 15, 2023 under the Military Medical Research and Development program (CFDA 12.420), supports a 4-year research project titled "Optimizing a Surveillance Strategy to Tackle Breast Cancer Dormancy and Minimal Residual Disease" to be conducted by the Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The objective of this research is...
- This federal Project Grant award of $4,277,148.00 from the Defense Health Agency under the CFDA Program 12.420 - Military Medical Research and Development supports research to identify molecular predictors of risk and objectively validate the evolution of ductal carcinoma in situ (DCIS). The award, effective September 30, 2023, with an ultimate completion date of September 29, 2027, will be performed at Stanford University. Through this grant, Stanford University will conduct basic,...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Institute For Cancer Research a $1,959,353 project grant effective September 1, 2025 through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). This award supports clinical research investigating pembrolizumab maintenance therapy following enfortumab vedotin/pembrolizumab induction treatment in front-line metastatic urothelial carcinoma. The research will be conducted at the...